The DOI matches its Crossref record; 77 of the 77 references it cites were found in a registry or an index.
Toxicity and management in CAR T-cell therapy
Open accessAbstract
T cells can be genetically modified to target tumors through the expression of a chimeric antigen receptor (CAR). Most notably, CAR T cells have demonstrated clinical efficacy in hematologic malignancies with more modest responses when targeting solid tumors. However, CAR T cells also have the capacity to elicit expected and unexpected toxicities including: cytokine release syndrome, neurologic toxicity, "on target/off tumor" recognition, and anaphylaxis. Theoretical toxicities including clonal expansion secondary to insertional oncogenesis, graft versus host disease, and off-target antigen recognition have not been clinically evident. Abrogating toxicity has become a critical step in the successful application of this emerging technology. To this end, we review the reported and theoretical toxicities of CAR T cells and their management.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Chimeric Antigen Receptor T Cells for Sustained Remissions in Leukemia
Maude, S. L., Frey, N., Shaw, P. A., Aplenc, R., Barrett, D. M., Bunin, N. J., Chew, A., Gonzalez, V. E., Zheng, Z., Lacey, S. F., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1407222 · Cited by 5,413
LMO2 -Associated Clonal T Cell Proliferation in Two Patients after Gene Therapy for SCID-X1
Hacein-Bey-Abina, S., Von Kalle, C., Schmidt, M., McCormack, M. P., Wulffraat, N., Leboulch, P., Lim, A., Osborne, C. S., Pawliuk, R., Morillon, E., et al. (2003) · Science · doi:10.1126/science.1088547 · Cited by 3,587
Chimeric Antigen Receptor–Modified T Cells for Acute Lymphoid Leukemia
Grupp, S. A., Kalos, M., Barrett, D., Aplenc, R., Porter, D. L., Rheingold, S. R., Teachey, D. T., Chew, A., Hauck, B., Wright, J. F., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1215134 · Cited by 3,509
Lee, D. W., Kochenderfer, J. N., Stetler-Stevenson, M., Cui, Y. K., Delbrook, C., Feldman, S. A., Fry, T. J., Orentas, R., Sabatino, M., Shah, N. N., et al. (2015) · The Lancet · doi:10.1016/s0140-6736(14)61403-3 · Cited by 2,898
Current concepts in the diagnosis and management of cytokine release syndrome.
Lee, D. W., Gardner, R., Porter, D. L., Louis, C. U., Ahmed, N., Jensen, M., Grupp, S. A., & Mackall, C. L. (2014) · Blood · doi:10.1182/blood-2014-05-552729 · Cited by 2,806
Morgan, R. A., Yang, J. C., Kitano, M., Dudley, M. E., Laurencot, C. M., & Rosenberg, S. A. (2010) · Molecular Therapy · doi:10.1038/mt.2010.24 · Cited by 2,533
Efficacy and Toxicity Management of 19-28z CAR T Cell Therapy in B Cell Acute Lymphoblastic Leukemia
Davila, M. L., Riviere, I., Wang, X., Bartido, S., Park, J., Curran, K., Chung, S. S., Stefanski, J., Borquez-Ojeda, O., Olszewska, M., et al. (2014) · Science Translational Medicine · doi:10.1126/scitranslmed.3008226 · Cited by 2,476
Self-citationCytokine Storm in a Phase 1 Trial of the Anti-CD28 Monoclonal Antibody TGN1412
Suntharalingam, G., Perry, M. R., Ward, S., Brett, S. J., Castello-Cortes, A., Brunner, M. D., & Panoskaltsis, N. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa063842 · Cited by 2,164
Brentjens, R. J., Davila, M. L., Riviere, I., Park, J., Wang, X., Cowell, L. G., Bartido, S., Stefanski, J., Taylor, C., Olszewska, M., et al. (2013) · Science Translational Medicine · doi:10.1126/scitranslmed.3005930 · Cited by 2,063
Self-citationInsertional oncogenesis in 4 patients after retrovirus-mediated gene therapy of SCID-X1
Hacein-Bey-Abina, S., Garrigue, A., Wang, G. P., Soulier, J., Lim, A., Morillon, E., Clappier, E., Caccavelli, L., Delabesse, E., Beldjord, K., et al. (2008) · Journal of Clinical Investigation · doi:10.1172/jci35700 · Cited by 1,854
Adoptive cell transfer: a clinical path to effective cancer immunotherapy
Rosenberg, S. A., Restifo, N. P., Yang, J. C., Morgan, R. A., & Dudley, M. E. (2008) · Nature Reviews Cancer · doi:10.1038/nrc2355 · Cited by 1,659
Eshhar, Z., Waks, T., Gross, G., & Schindler, D. G. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.2.720 · Cited by 1,658
Inducible Apoptosis as a Safety Switch for Adoptive Cell Therapy
Di Stasi, A., Tey, S.-K., Dotti, G., Fujita, Y., Kennedy-Nasser, A., Martinez, C., Straathof, K., Liu, E., Durett, A. G., Grilley, B., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1106152 · Cited by 1,512
Kochenderfer, J. N., Dudley, M. E., Feldman, S. A., Wilson, W. H., Spaner, D. E., Maric, I., Stetler-Stevenson, M., Phan, G. Q., Hughes, M. S., Sherry, R. M., et al. (2012) · Blood · doi:10.1182/blood-2011-10-384388 · Cited by 1,440
Kochenderfer, J. N., Wilson, W. H., Janik, J. E., Dudley, M. E., Stetler-Stevenson, M., Feldman, S. A., Maric, I., Raffeld, M., Nathan, D.-A. N., Lanier, B. J., et al. (2010) · Blood · doi:10.1182/blood-2010-04-281931 · Cited by 1,337
Howe, S. J., Mansour, M. R., Schwarzwaelder, K., Bartholomae, C., Hubank, M., Kempski, H., Brugman, M. H., Pike-Overzet, K., Chatters, S. J., de Ridder, D., et al. (2008) · Journal of Clinical Investigation · doi:10.1172/jci35798 · Cited by 1,286
Topp, M. S., Gökbuget, N., Stein, A. S., Zugmaier, G., O'Brien, S., Bargou, R. C., Dombret, H., Fielding, A. K., Heffner, L., Larson, R. A., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(14)71170-2 · Cited by 1,269
A Phase I Study on Adoptive Immunotherapy Using Gene-Modified T Cells for Ovarian Cancer
Kershaw, M. H., Westwood, J. A., Parker, L. L., Wang, G., Eshhar, Z., Mavroukakis, S. A., White, D. E., Wunderlich, J. R., Canevari, S., Rogers-Freezer, L., et al. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-1183 · Cited by 1,254
Linette, G. P., Stadtmauer, E. A., Maus, M. V., Rapoport, A. P., Levine, B. L., Emery, L., Litzky, L., Bagg, A., Carreno, B. M., Cimino, P. J., et al. (2013) · Blood · doi:10.1182/blood-2013-03-490565 · Cited by 1,179
HSV-TK Gene Transfer into Donor Lymphocytes for Control of Allogeneic Graft-Versus-Leukemia
Bonini, C., Ferrari, G., Verzeletti, S., Servida, P., Zappone, E., Ruggieri, L., Ponzoni, M., Rossini, S., Mavilio, F., Traversari, C., et al. (1997) · Science · doi:10.1126/science.276.5319.1719 · Cited by 1,161
Parkhurst, M. R., Yang, J. C., Langan, R. C., Dudley, M. E., Nathan, D.-A. N., Feldman, S. A., Davis, J. L., Morgan, R. A., Merino, M. J., Sherry, R. M., et al. (2011) · Molecular Therapy · doi:10.1038/mt.2010.272 · Cited by 1,020
Ahmed, N., Brawley, V. S., Hegde, M., Robertson, C., Ghazi, A., Gerken, C., Liu, E., Dakhova, O., Ashoori, A., Corder, A., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.58.0225 · Cited by 1,004
Lamers, C. H. J., Sleijfer, S., Vulto, A. G., Kruit, W. H. J., Kliffen, M., Debets, R., Gratama, J. W., Stoter, G., & Oosterwijk, E. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2006.05.9964 · Cited by 915
Kloss, C. C., Condomines, M., Cartellieri, M., Bachmann, M., & Sadelain, M. (2013) · Nature Biotechnology · doi:10.1038/nbt.2459 · Cited by 857
Heslop, H. E., Slobod, K. S., Pule, M. A., Hale, G. A., Rousseau, A., Smith, C. A., Bollard, C. M., Liu, H., Wu, M.-F., Rochester, R. J., et al. (2010) · Blood · doi:10.1182/blood-2009-08-239186 · Cited by 780
Managing Cytokine Release Syndrome Associated With Novel T Cell-Engaging Therapies
Maude, S. L., Barrett, D., Teachey, D. T., & Grupp, S. A. (2014) · The Cancer Journal · doi:10.1097/ppo.0000000000000035 · Cited by 752
Fedorov, V. D., Themeli, M., & Sadelain, M. (2013) · Science Translational Medicine · doi:10.1126/scitranslmed.3006597 · Cited by 735
Stein, S., Ott, M. G., Schultze-Strasser, S., Jauch, A., Burwinkel, B., Kinner, A., Schmidt, M., Krämer, A., Schwäble, J., Glimm, H., et al. (2010) · Nature Medicine · doi:10.1038/nm.2088 · Cited by 716
Lamers, C. H., Sleijfer, S., van Steenbergen, S., van Elzakker, P., van Krimpen, B., Groot, C., Vulto, A., den Bakker, M., Oosterwijk, E., Debets, R., et al. (2013) · Molecular Therapy · doi:10.1038/mt.2013.17 · Cited by 704
Remote control of therapeutic T cells through a small molecule–gated chimeric receptor
Wu, C.-Y., Roybal, K. T., Puchner, E. M., Onuffer, J., & Lim, W. A. (2015) · Science · doi:10.1126/science.aab4077 · Cited by 687
Cameron, B. J., Gerry, A. B., Dukes, J., Harper, J. V., Kannan, V., Bianchi, F. C., Grand, F., Brewer, J. E., Gupta, M., Plesa, G., et al. (2013) · Science Translational Medicine · doi:10.1126/scitranslmed.3006034 · Cited by 684
Winkler, U., Jensen, M., Manzke, O., Schulz, H., Diehl, V., & Engert, A. (1999) · Blood · doi:10.1182/blood.v94.7.2217.419k02_2217_2224 · Cited by 657
Decade-Long Safety and Function of Retroviral-Modified Chimeric Antigen Receptor T Cells
Scholler, J., Brady, T. L., Binder-Scholl, G., Hwang, W.-T., Plesa, G., Hege, K. M., Vogel, A. N., Kalos, M., Riley, J. L., Deeks, S. G., et al. (2012) · Science Translational Medicine · doi:10.1126/scitranslmed.3003761 · Cited by 652
Teachey, D. T., Rheingold, S. R., Maude, S. L., Zugmaier, G., Barrett, D. M., Seif, A. E., Nichols, K. E., Suppa, E. K., Kalos, M., Berg, R. A., et al. (2013) · Blood · doi:10.1182/blood-2013-02-485623 · Cited by 613
Poirot, L., Philip, B., Schiffer-Mannioui, C., Le Clerre, D., Chion-Sotinel, I., Derniame, S., Potrel, P., Bas, C., Lemaire, L., Galetto, R., et al. (2015) · Cancer Research · doi:10.1158/0008-5472.can-14-3321 · Cited by 605
Wang, X., Chang, W.-C., Wong, C. W., Colcher, D., Sherman, M., Ostberg, J. R., Forman, S. J., Riddell, S. R., & Jensen, M. C. (2011) · Blood · doi:10.1182/blood-2011-02-337360 · Cited by 600
Kochenderfer, J. N., Dudley, M. E., Carpenter, R. O., Kassim, S. H., Rose, J. J., Telford, W. G., Hakim, F. T., Halverson, D. C., Fowler, D. H., Hardy, N. M., et al. (2013) · Blood · doi:10.1182/blood-2013-08-519413 · Cited by 590
T Cells Expressing Chimeric Antigen Receptors Can Cause Anaphylaxis in Humans
Maus, M. V., Haas, A. R., Beatty, G. L., Albelda, S. M., Levine, B. L., Liu, X., Zhao, Y., Kalos, M., & June, C. H. (2013) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-13-0006 · Cited by 586
Graft-versus-leukemia effects of transplantation and donor lymphocytes
Kolb, H.-J. (2008) · Blood · doi:10.1182/blood-2008-03-077974 · Cited by 582
Targeting tumours with genetically enhanced T lymphocytes
Sadelain, M., Rivière, I., & Brentjens, R. (2003) · Nature Reviews Cancer · doi:10.1038/nrc971 · Cited by 535
Self-citationJensen, M. C., Popplewell, L., Cooper, L. J., DiGiusto, D., Kalos, M., Ostberg, J. R., & Forman, S. J. (2010) · Biology of Blood and Marrow Transplantation · doi:10.1016/j.bbmt.2010.03.014 · Cited by 529
Cruz, C. R. Y., Micklethwaite, K. P., Savoldo, B., Ramos, C. A., Lam, S., Ku, S., Diouf, O., Liu, E., Barrett, A. J., Ito, S., et al. (2013) · Blood · doi:10.1182/blood-2013-06-506741 · Cited by 508
Wilkie, S., van Schalkwyk, M. C. I., Hobbs, S., Davies, D. M., van der Stegen, S. J. C., Pereira, A. C. P., Burbridge, S. E., Box, C., Eccles, S. A., & Maher, J. (2012) · Journal of Clinical Immunology · doi:10.1007/s10875-012-9689-9 · Cited by 478
Exploiting the curative potential of adoptive T‐cell therapy for cancer
Hinrichs, C. S., & Rosenberg, S. A. (2014) · Immunological Reviews · doi:10.1111/imr.12132 · Cited by 466
A highly compact epitope-based marker/suicide gene for easier and safer T-cell therapy
Philip, B., Kokalaki, E., Mekkaoui, L., Thomas, S., Straathof, K., Flutter, B., Marin, V., Marafioti, T., Chakraverty, R., Linch, D., et al. (2014) · Blood · doi:10.1182/blood-2014-01-545020 · Cited by 397
Lamers, C. H. J., Willemsen, R., van Elzakker, P., van Steenbergen-Langeveld, S., Broertjes, M., Oosterwijk-Wakka, J., Oosterwijk, E., Sleijfer, S., Debets, R., & Gratama, J. W. (2011) · Blood · doi:10.1182/blood-2010-07-294520 · Cited by 368
Occurrence of leukaemia following gene therapy of X-linked SCID
Kohn, D. B., Sadelain, M., & Glorioso, J. C. (2003) · Nature Reviews Cancer · doi:10.1038/nrc1122 · Cited by 344
STUDIES ON THE IMMUNOLOGICAL RESPONSE TO FOREIGN TUMOR TRANSPLANTS IN THE MOUSE
Mitchison, N. A. (1955) · The Journal of Experimental Medicine · doi:10.1084/jem.102.2.157 · Cited by 326
CHATENOUD, L., FERRAN, C., LEGENDRE, C., THOUARD, I., MERITE, S., REUTER, A., GEVAERT, Y., KREIS, H., FRANCHIMONT, P., & BACH, J.-F. (1990) · Transplantation · doi:10.1097/00007890-199004000-00009 · Cited by 320
Hollyman, D., Stefanski, J., Przybylowski, M., Bartido, S., Borquez-Ojeda, O., Taylor, C., Yeh, R., Capacio, V., Olszewska, M., Hosey, J., et al. (2009) · Journal of Immunotherapy · doi:10.1097/cji.0b013e318194a6e8 · Cited by 316
Self-citationWing, M. G., Moreau, T., Greenwood, J., Smith, R. M., Hale, G., Isaacs, J., Waldmann, H., Lachmann, P. J., & Compston, A. (1996) · Journal of Clinical Investigation · doi:10.1172/jci119110 · Cited by 257
Chimeric antigen receptors for T cell immunotherapy: current understanding and future directions
Curran, K. J., Pegram, H. J., & Brentjens, R. J. (2012) · The Journal of Gene Medicine · doi:10.1002/jgm.2604 · Cited by 251
Self-citationA Fas-based suicide switch in human T cells for the treatment of graft-versus-host disease
Thomis, D. C. (2001) · Blood · doi:10.1182/blood.v97.5.1249 · Cited by 205
Tey, S.-K., Dotti, G., Rooney, C. M., Heslop, H. E., & Brenner, M. K. (2007) · Biology of Blood and Marrow Transplantation · doi:10.1016/j.bbmt.2007.04.005 · Cited by 204
New cell sources for T cell engineering and adoptive immunotherapy
Themeli, M., Rivière, I., & Sadelain, M. (2015) · Cell stem cell · doi:10.1016/j.stem.2015.03.011 · Cited by 179
Zhou, X., Di Stasi, A., Tey, S.-K., Krance, R. A., Martinez, C., Leung, K. S., Durett, A. G., Wu, M.-F., Liu, H., Leen, A. M., et al. (2014) · Blood · doi:10.1182/blood-2014-01-551671 · Cited by 172
Cavalieri, S., Cazzaniga, S., Geuna, M., Magnani, Z. I., Bordignon, C., Naldini, L., & Bonini, C. (2003) · Blood · doi:10.1182/blood-2003-01-0297 · Cited by 166
Vera, J. F., Brenner, L. J., Gerdemann, U., Ngo, M. C., Sili, U., Liu, H., Wilson, J., Dotti, G., Heslop, H. E., Leen, A. M., et al. (2010) · Journal of Immunotherapy · doi:10.1097/cji.0b013e3181c0c3cb · Cited by 165
Bordignon, C., Bonini, C., Verzeletti, S., Nobili, N., Maggioni, D., Traversari, C., Giavazzi, R., Servida, P., Zappone, E., Benazzi, E., et al. (1995) · Human Gene Therapy · doi:10.1089/hum.1995.6.6-813 · Cited by 153
Jin, J., Sabatino, M., Somerville, R. P. T., Wilson, J. R., Dudley, M. E., Stroncek, D. F., & Rosenberg, S. A. (2012) · Journal of Immunotherapy · doi:10.1097/cji.0b013e31824e801f · Cited by 152
Forecasting the cytokine storm following systemic interleukin (IL)-2 administration
Panelli, M. C., White, R., Foster, M., Martin, B., Wang, E., Smith, K., & Marincola, F. M. (2004) · Journal of Translational Medicine · doi:10.1186/1479-5876-2-17 · Cited by 139
Marin, V., Cribioli, E., Philip, B., Tettamanti, S., Pizzitola, I., Biondi, A., Biagi, E., & Pulè, M. A. (2012) · Human Gene Therapy Methods · doi:10.1089/hgtb.2012.050 · Cited by 127
Serafini, M., Manganini, M., Borleri, G., Bonamino, M., Imberti, L., Biondi, A., Golay, J., Rambaldi, A., & Introna, M. (2004) · Human Gene Therapy · doi:10.1089/10430340460732463 · Cited by 110
Engineered Human tmpk/AZT As a Novel Enzyme/Prodrug Axis for Suicide Gene Therapy
Sato, T., Neschadim, A., Konrad, M., Fowler, D. H., Lavie, A., & Medin, J. A. (2007) · Molecular Therapy · doi:10.1038/mt.sj.6300122 · Cited by 103
Somerville, R. P. T., Devillier, L., Parkhurst, M. R., Rosenberg, S. A., & Dudley, M. E. (2012) · Journal of Translational Medicine · doi:10.1186/1479-5876-10-69 · Cited by 97
Tiberghien, P., Cahn, J.-Y. Y., Brion, A., Deconinck, É., Racadot, E., Hervé, P., Milpied, N. J., Lioure, B., Gluckman, E., Bordigoni, P., et al. (1997) · Human Gene Therapy · doi:10.1089/hum.1997.8.5-615 · Cited by 80
Wang, X., Wong, C. W., Urak, R. Z., Mardiros, A., Budde, L. E., Chang, W.-C., Thomas, S. H., Brown, C. E., Rosa, C. L., Diamond, D. J., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-2920 · Cited by 71
Buie, L. W., Pecoraro, J. J., Horvat, T. Z., & Daley, R. J. (2015) · Annals of Pharmacotherapy · doi:10.1177/1060028015588555 · Cited by 67
Overcoming the toxicity hurdles of genetically targeted T cells
Casucci, M., Hawkins, R. E., Dotti, G., & Bondanza, A. (2014) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-014-1641-9 · Cited by 57
Zhou, X., Cui, Y. R., Huang, X., Yu, Z., Thomas, A. M., Ye, Z., Pardoll, D. M., Jaffee, E. M., & Cheng, L. (2003) · Human Gene Therapy · doi:10.1089/104303403322124800 · Cited by 53
Titin: central player of hypertrophic signaling and sarcomeric protein quality control
Kötter, S., Andresen, C., & Krüger, M. (2014) · Biological Chemistry · doi:10.1515/hsz-2014-0178 · Cited by 48
Ando, M., Hoyos, V., Yagyu, S., Tao, W., Ramos, C. A., Dotti, G., Brenner, M. K., & Bouchier‐Hayes, L. (2014) · Cancer Gene Therapy · doi:10.1038/cgt.2014.53 · Cited by 46
Antigen-specific T cell therapies for cancer: Figure 1.
Manzo, T., Heslop, H. E., & Rooney, C. M. (2015) · Human Molecular Genetics · doi:10.1093/hmg/ddv270 · Cited by 38
Sun, J., Huye, L. E., Lapteva, N., Mamonkin, M., Hiregange, M., Ballard, B. C., Dakhova, O., Raghavan, D., Durett, A. G., Perna, S. K., et al. (2015) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-015-0049-1 · Cited by 30
Maude, S. L., Barrett, D. M., Ambrose, D. E., Rheingold, S. R., Aplenc, R., Teachey, D. T., Callahan, C. A., Barker, C. S., Mudambi, M., Shaw, P. A., et al. (2015) · Blood · doi:10.1182/blood.v126.23.683.683 · Cited by 29
Preparing clinical grade Ag-specific T cells for adoptive immunotherapy trials
DiGiusto, D. L., & Cooper, L. J. N. (2007) · Cytotherapy · doi:10.1080/14653240701650320 · Cited by 27
T-cell receptor gene therapy for cancer: the progress to date and future objectives
Thomas, S., Hart, D. P., Xue, S., Cesco-Gaspere, M., & Stauss, H. J. (2007) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.7.8.1207 · Cited by 21
Cited by
Inflammation and tumor progression: signaling pathways and targeted intervention
Zhao, H., Wu, L., Yan, G., Chen, Y., Zhou, M., Wu, Y., & Li, Y. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00658-5 · Cited by 2,792
Chimeric antigen receptor T-cell therapy—assessment and management of toxicities
Neelapu, S. S., Tummala, S., Kebriaei, P., Wierda, W., Gutierrez, C., Locke, F. L., Komanduri, K. V., Lin, Y., Jain, N., Daver, N., et al. (2018) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2017.148 · Cited by 2,438
Shimabukuro-Vornhagen, A., Gödel, P., Subklewe, M., Stemmler, H. J., Schlößer, H. A., Schlaak, M., Kochanek, M., Böll, B., & von Bergwelt-Baildon, M. S. (2018) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-018-0343-9 · Cited by 1,656
CAR T cell–induced cytokine release syndrome is mediated by macrophages and abated by IL-1 blockade
Giavridis, T., van der Stegen, S. J. C., Eyquem, J., Hamieh, M., Piersigilli, A., & Sadelain, M. (2018) · Nature Medicine · doi:10.1038/s41591-018-0041-7 · Cited by 1,272
Liu, E., Tong, Y., Dotti, G., Shaim, H., Savoldo, B., Mukherjee, M., Orange, J., Wan, X., Lu, X., Reynolds, A., et al. (2018) · Leukemia · doi:10.1038/leu.2017.226 · Cited by 824
Metadata
- Authors
- Bonifant, C. L., Jackson, H. J., Brentjens, R. J., & Curran, K. J.
- Venue
- Molecular Therapy - Oncolytics
- Publisher
- Elsevier BV
- Published
- 2016
- Volume
- 3
- Pages
- 16011
- ISSN
- 2372-7705 (ISSN-L)
- OpenAlex
- W2335984750
- Cited by
- 885
- References
- 77
- FWCI
- 40.02
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.